Novartis
Novartis Divests Xiidra and Other Ophthalmology Assets to Bausch + Lomb for $2.5 Billion
SG Tylor
Source – Novartis In a strategic move to concentrate on its core areas, Novartis has decided to transfer the dry ...
To speed up patient access to Biosimilar medications, Sandoz announces the Act4 Biosimilars Action Plan
SG Tylor
Source – Novartis On June 15, a global plan to improve patient access to biologic medicines was launched, according to ...
Novartis has agreed to purchase Chinook Therapeutics for USD 3.2 billion upfront (USD 40 per share), strengthening its new medicines strategy and renal portfolio in the process
SG Tylor
On 12 June 2023 Novartis revealed that it has reached a deal to purchase Chinook Therapeutics, a clinical-stage biopharmaceutical business ...
Novartis Survey Challenges Perception of CML as a Resolved Disease, Revealing Ongoing Impact and Need for Attention
SG Tylor
Source: Novartis On June 9, 2023, Novartis reveals CML (chronic myeloid leukemia) SUN Results at 2023 European Hematology Association (EHA) ...
EU Regulators Call for Withdrawal of Authorization for Novartis’ Sickle Cell Drug Adakveo Following Phase 3 Setback
SG Tylor
After the phase 3 trial of Novartis’ sickle cell disease drug, Adakveo, yielded disappointing results, regulators in Europe have revisited ...
